Cipla Limited and its wholly owned subsidiary, Cipla USA Inc., announced the commercial launch of Pomalidomide Capsules in the United States. The generic equivalent of Bristol Myers Squibb’s Pomalyst® is available across all dosage strengths: 1 mg, 2 mg, 3 mg, and 4 mg.
Pomalidomide capsules are indicated for the treatment of adult patients with multiple myeloma, taken in combination with dexamethasone, who have received at least two prior therapies, including a proteasome inhibitor and lenalidomide, and have demonstrated disease progression. The medication is also indicated for adult patients with AIDS-related Kaposi sarcoma (KS) following the failure of highly active antiretroviral therapy (HAART), as well as adult patients with HIV-negative KS. According to IQVIA data, Pomalidomide Capsules recorded estimated sales of approximately USD 2.69 billion for the twelve months ending June 2026.
To ensure patient safety and maintain compliance with FDA guidelines, Cipla is participating in the shared PS-PomalidomideRisk Evaluation and Mitigation Strategy (REMS) program. The product is manufactured at Cipla’s approved manufacturing facility, ensuring reliable, uninterrupted commercial supply.
“This launch reinforces Cipla’s long-standing commitment to expanding access to high-quality, affordable oncology therapies,” said Marc Falkin, Chief Executive Officer of CiplaNorth America. “As we continue to build a comprehensive portfolio across the treatment continuum, our focus remains on improving patient outcomes, addressing barriers to care, and supporting continuity of treatment, including through co-pay assistance programs for eligible patients.”
Written by: Pragna Biswas
Graphics by: Pramit Hazra
